Reimbursement

Top articles of the week on Specialty Pharmacy Times.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.

Developing industry connections is crucial for aspiring pharmacists.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses how to address the challenge of access to high cost specialty medications.

An award of $347 million has been given to 16 organizations involved with the Hospital Improvement and Innovation Network.

The University of Pittsburgh’s Masters of Science in Pharmacy Business Administration program catalyzes the critical skills and expertise necessary for students to reach their professional goals.

Zitter Health Insights and Specialty Pharmacy Times partner to recognize the top performing specialty pharmacies based on patient satisfaction.

Core services are basic to specialty pharmacy offerings, while enhanced services are only provided with payment from a third party, usually a drug manufacturer.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.

Rebekah L. Hanson, PharmD, BCPS, BCACP, clinical pharmacist and assistant professor at the UIC College of Pharmacy, discusses the challenge of out-of-pocket spending and the impact on drug adherence.

Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses challenges for patients in accessing specialty medications.

Top articles of the week on Specialty Pharmacy Times.

Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses challenges balancing the quality of care with the high cost of treatments.

Eric Peacock, co-founder and CEO of MyHealthTeams, how bringing the voice of patients to clinical research can enhance health care.

Daniel P. Kus, BS Pharm, RPh, discusses how the growth of drug prices could impact the specialty pharmacy patient experience.

Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses how specialty pharmacies can navigate limited distribution networks.

The initial encounter between a patient and a specialty pharmacy is crucial to the long-term success of the partnership.

Top articles of the week on Specialty Pharmacy Times.

Rebekah L. Hanson, PharmD, BCPS, BCACP, clinical pharmacist and assistant professor at the UIC College of Pharmacy, discusses medication management processes that can improve adherence to specialty therapies.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses actions that can enhance the relationship between manufacturers, payers, providers and patients in specialty pharmacy.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses the out-of-pocket costs that can emerge for patients starting a specialty medication regimen.

Paul LeVine, vice president of Analytic Services at TrialCard, discusses how specialty pharmacies can use patient feedback surveys to improve treatment outcomes.

Pharmacist interventions can help improve medication adherence among patients in predominantly African-American and Hispanic communities.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses the components of an effective patient management program to optimize adherence.

Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses the challenges of access to high cost specialty medications.

Top news of the day from across the healthcare landscape.

Researchers examine how socialization institutes effect the way individuals in low income areas relate to HIV/AIDS after a natural disaster.

The Right to Try Act allows terminally ill patients to take investigational treatments that have passed basic safety testing.

Heart failure-related apps that monitor symptoms fall short of expectations.

Study finds high out-of-pocket costs remain a barrier for initiation of oral cancer drugs.